Abstract

Despite our extensive knowledge on the biology of protein kinase C (PKC) and its involvement in disease, limited success has been attained in the generation of PKC isozyme-specific modulators acting via the C1 domain, the binding site for the lipid second messenger diacylglycerol (DAG) and the phorbol ester tumor promoters. Synthetic efforts had recently led to the identification of AJH-836, a DAG-lactone with preferential affinity for novel isozymes (nPKCs) relative to classical PKCs (cPKCs). Here, we compared the ability of AJH-836 and a prototypical phorbol ester (phorbol 12-myristate 13-acetate, PMA) to induce changes in gene expression in a lung cancer model. Gene profiling analysis using RNA-Seq revealed that PMA caused major changes in gene expression, whereas AJH-836 only induced a small subset of genes, thus providing a strong indication for a major involvement of cPKCs in their control of gene expression. MMP1, MMP9, and MMP10 were among the genes most prominently induced by PMA, an effect impaired by RNAi silencing of PKCα, but not PKCδ or PKCε. Comprehensive gene signature analysis and bioinformatics efforts, including functional enrichment and transcription factor binding site analyses of dysregulated genes, identified major differences in pathway activation and transcriptional networks between PMA and DAG-lactones. In addition to providing solid evidence for the differential involvement of individual PKC isozymes in the control of gene expression, our studies emphasize the importance of generating targeted C1 domain ligands capable of differentially regulating PKC isozyme-specific function in cellular models.

Highlights

  • Consistent with the contrasting effects of individual protein kinase C (PKC) isozymes in promoting or suppressing tumor growth, it is widely recognized that discrete members of this family can have either similar or opposite roles in a cellular context[4,5,6]

  • In addition to PKCs, a number of other proteins with C1 domains are capable of binding DAG and phorbol esters with high affinity, including protein kinase D (PKD1, 2, and 3), lipid kinases (DAG-kinases/DGKs), regulators of small GTPases, and proteins involved in exocytosis/trafficking (Munc-13 isozymes)[1,3]

  • Towards our objective of establishing whether the selectivity of C1 domain ligands could be reflected in differential biological outcomes, we decided to compare the ability of AJH-836 and PMA to modulate gene expression

Read more

Summary

Introduction

Consistent with the contrasting effects of individual PKC isozymes in promoting or suppressing tumor growth, it is widely recognized that discrete members of this family can have either similar or opposite roles in a cellular context[4,5,6]. Phorbol esters and related compounds, such as bryostatins and deoxyphorbol esters, have similar affinities in vitro for individual PKC isozymes[18,22] These agents exert distinctive biological responses in cellular and animal models[26,27,28], possibly reflecting their differential ability to insert into membranes, the formation of particular protein-ligand-membrane ternary complexes, and/or specific ligand interactions with lipid microdomains[29,30,31]. We developed DAG-lactones with the incorporation of linoleic acid derivatives as well as saturated and unsaturated alkyl chain substitutions, which provided compounds with preferential affinity for nPKCs35,36 One of these C1 domain ligands, the DAG-lactone (E)-(2-(hydroxymethyl)-4-(3-isobutyl-5-methylhexylidene)5-oxotetrahydrofuran-2-yl) methyl pivalate (AJH-836), has marked selectivity in vitro for PKCδ and PKCε relative to PKCα and PKCβ. Our results revealed major differences in the transcriptional activation and repression of genes in a lung cancer model, providing strong evidence for the differential involvement of PKC isozymes in the control of gene expression in this system, and further emphasizing the importance of generating targeted C1 domain ligands to dissect isozyme-specific biological outcomes

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call